OBJECTIVE: Loss-of-function mutations in human hepatocyte nuclear factor 4α (HNF4α) are associated with maturity-onset diabetes of the young and lipid disorders. However, the mechanisms underlying the lipid disorders are poorly understood. In this study, we determined the effect of acute loss or augmentation of hepatic HNF4α function on lipid homeostasis. METHODS AND RESULTS: We generated an adenovirus expressing LacZ (Ad-shLacZ) or short hairpin RNA of Hnf4α (Ad-shHnf4α). Tail vain injection of C57BL/6J mice with Ad-shHnf4α reduced hepatic Hnf4α expression and resulted in striking phenotypes, including the development of fatty liver and a >80% decrease in plasma levels of triglycerides, total cholesterol, and high-density lipoprotein cholesterol. These latter changes were associated with reduced hepatic lipogenesis and impaired very-low-density lipoprotein secretion. Deficiency in hepatic Hnf4α did not affect intestinal cholesterol absorption despite decreased expression of genes involved in bile acid synthesis. Consistent with the loss-of-function data, overexpression of Hnf4α induced numerous genes involved in lipid metabolism in isolated primary hepatocytes. Interestingly, many of these HNF4α-regulated genes were not induced in wild-type mice that overexpressed hepatic Hnf4α. Because of selective gene regulation, mice overexpressing hepatic Hnf4α had unchanged plasma triglyceride levels and decreased plasma cholesterol levels. CONCLUSIONS: Loss of hepatic HNF4α results in severe lipid disorder as a result of dysregulation of multiple genes involved in lipid metabolism. In contrast, augmentation of hepatic HNF4α activity lowers plasma cholesterol levels but has no effect on plasma triglyceride levels because of selective gene regulation. Our data indicate that hepatic HNF4α is essential for controlling the basal expression of numerous genes involved in lipid metabolism and is indispensable for maintaining normal lipid homeostasis.
OBJECTIVE: Loss-of-function mutations in human hepatocyte nuclear factor 4α (HNF4α) are associated with maturity-onset diabetes of the young and lipid disorders. However, the mechanisms underlying the lipid disorders are poorly understood. In this study, we determined the effect of acute loss or augmentation of hepatic HNF4α function on lipid homeostasis. METHODS AND RESULTS: We generated an adenovirus expressing LacZ (Ad-shLacZ) or short hairpin RNA of Hnf4α (Ad-shHnf4α). Tail vain injection of C57BL/6J mice with Ad-shHnf4α reduced hepatic Hnf4α expression and resulted in striking phenotypes, including the development of fatty liver and a >80% decrease in plasma levels of triglycerides, total cholesterol, and high-density lipoprotein cholesterol. These latter changes were associated with reduced hepatic lipogenesis and impaired very-low-density lipoprotein secretion. Deficiency in hepatic Hnf4α did not affect intestinal cholesterol absorption despite decreased expression of genes involved in bile acid synthesis. Consistent with the loss-of-function data, overexpression of Hnf4α induced numerous genes involved in lipid metabolism in isolated primary hepatocytes. Interestingly, many of these HNF4α-regulated genes were not induced in wild-type mice that overexpressed hepatic Hnf4α. Because of selective gene regulation, mice overexpressing hepatic Hnf4α had unchanged plasma triglyceride levels and decreased plasma cholesterol levels. CONCLUSIONS: Loss of hepatic HNF4α results in severe lipid disorder as a result of dysregulation of multiple genes involved in lipid metabolism. In contrast, augmentation of hepatic HNF4α activity lowers plasma cholesterol levels but has no effect on plasma triglyceride levels because of selective gene regulation. Our data indicate that hepatic HNF4α is essential for controlling the basal expression of numerous genes involved in lipid metabolism and is indispensable for maintaining normal lipid homeostasis.
Authors: M Bodzioch; E Orsó; J Klucken; T Langmann; A Böttcher; W Diederich; W Drobnik; S Barlage; C Büchler; M Porsch-Ozcürümez; W E Kaminski; H W Hahmann; K Oette; G Rothe; C Aslanidis; K J Lackner; G Schmitz Journal: Nat Genet Date: 1999-08 Impact factor: 38.330
Authors: M Lehto; P O Bitzén; B Isomaa; C Wipemo; Y Wessman; C Forsblom; T Tuomi; M R Taskinen; L Groop Journal: Diabetes Date: 1999-02 Impact factor: 9.461
Authors: Jenelle M Timmins; Ji-Young Lee; Elena Boudyguina; Kimberly D Kluckman; Liam R Brunham; Anny Mulya; Abraham K Gebre; Jonathan M Coutinho; Perry L Colvin; Thomas L Smith; Michael R Hayden; Nobuyo Maeda; John S Parks Journal: J Clin Invest Date: 2005-04-07 Impact factor: 14.808
Authors: Yanqiao Zhang; Lawrence W Castellani; Christopher J Sinal; Frank J Gonzalez; Peter A Edwards Journal: Genes Dev Date: 2004-01-16 Impact factor: 11.361
Authors: Ilya R Bederman; Steven Foy; Visvanathan Chandramouli; James C Alexander; Stephen F Previs Journal: J Biol Chem Date: 2008-12-29 Impact factor: 5.157
Authors: Divya Mehta; Charles L Raison; Bobbi J Woolwine; Ebrahim Haroon; Elisabeth B Binder; Andrew H Miller; Jennifer C Felger Journal: Brain Behav Immun Date: 2013-04-25 Impact factor: 7.217
Authors: Salwa M Abo El-Khair; Fatma M Ghoneim; Dalia A Shabaan; Ayman Z Elsamanoudy Journal: Histochem Cell Biol Date: 2019-10-21 Impact factor: 4.304
Authors: Melanie Kahle; Marion Horsch; Barbara Fridrich; Anett Seelig; Jürgen Schultheiß; Jörn Leonhardt; Martin Irmler; Johannes Beckers; Birgit Rathkolb; Eckhard Wolf; Nicole Franke; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Susanne Neschen Journal: Mol Metab Date: 2013-08-03 Impact factor: 7.422